Gilead and ISCIII launch the 11th edition of Biomedical Research Grants

Gilead and ISCIII launch the 11th edition of Biomedical Research Grants

María Río, Vice President and General Manager of Gilead Sciences Spain and Portugal, and Marina Pollan, Director of the Carlos III Health Institute (ISCIII), a body of the Ministry of Science, Innovation and Universities, have signed a collaboration agreement with the 11th edition of Gilead Grants in Biomedical Research.

These scholarships, which aim to promote research and development in Spain and recognize the work of Spanish researchers, were introduced more than a decade ago, with an investment of around €1 million. The assistance is possible thanks to the collaboration between Gilead and ISCIII, an entity that ensures that the process of reviewing research projects complies with the principles of transparency, objectivity and independence necessary for the correct selection of projects to be funded.

“It gives me great pleasure to announce that the 11th edition of the Gilead Biomedical Innovation Grants is already underway. This initiative is one of the most important organized in our country in the field of research, and it is a matter of pride to see how Health Carles III: “It is strengthening how it continues to support Spanish researchers, and as always, the experience and proven track record of the Health Carles III Institute are guarantees of the rigor and scientific quality of the projects to be selected.” President and General Director of Gilead Spain and Portugal.

As Marina Pollan, Director of ISCIII, explained, “At the Institute, it seems very important for us to continue supporting this kind of public-private cooperation initiatives, which allow us to unite different ways of promoting health research. As in previous years, our participation in the evaluation These grant projects are a new example of ISCIII’s commitment to generating scientific knowledge to care for people’s health.”

See also  Introductory day for markets but directionality can start tomorrow

Recognition of excellence

Over the years, Gilead has incorporated various therapeutic areas to advance research in those areas and diseases that have urgent unmet medical needs. In this way, this edition will recognize the best research work in the field of HIV, COVID-19, delta hepatitis, B-cell non-Hodgkin lymphoma, and medical oncology, which will have collaboration with the major scientific societies and collaborative groups in these specialties. .

The evaluation of the projects will be carried out by ISCIII, an entity with its own experience and quality standards and the participation of national and international evaluators for each project.

In addition, in this eleventh edition – for the fourth year in a row – the works presented by young researchers will be honored. An initiative through which Gilead and ISCIII seek to highlight the research work and enhance the experience and talent of young Spanish scientists in various fields with medical needs that have not yet been covered.

Gilead Biomedical Research Grants were established in 2013 with the aim of promoting biomedical research in clinical care centers in Spain. Today it represents a benchmark in the Spanish healthcare sector, both in terms of investment made – around €1 million per year – and in terms of the number of projects approved. During this period, 185 projects from 13 autonomous regions were selected.

Initiatives to qualify for Gilead Grants in Biomedical Research must be drafted in English by Sunday, June 30 on the web.‘. Each Principal Investigator can submit only one research project and a maximum of two projects will be allowed per treatment area and healthcare center to which the Principal Investigator (PI) is associated. After that, the Carlos III Health Institute will be responsible for reviewing the projects and developing a list of priorities.

See also  On the highway about 2.5 euros per liter -

Leave a Reply

Your email address will not be published. Required fields are marked *